Acamprosate

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 3, 2010, Pages 363-380

  Kennedy, William Klugh ^a   Leloux, Megan ^b   Kutscher, Eric C ^b,c,d,e   Price, Paul L ^f,g   Morstad, Anne E ^b   Carnahan, Ryan M ^h,i  

^a MEMORIAL HEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b Avera Health   (United States)

^c SOUTH DAKOTA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTH DAKOTA   (United States)

^e Psychiatry Pharmacy Practice Residency Program (PGY II)   (United States)

^f CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Alegent Health Immanuel Medical Center   (United States)

^h UNIVERSITY OF IOWA   (United States)

ⁱ Iowa Older Adults Center for Education and Research on Therapeutics   (United States)

Author keywords

Abstinence; Abuse; Acamprosate; Addiction; Alcohol; Craving; Dependence; Ethanol; Glutamate; NMDA

Indexed keywords

ACAMPROSATE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BACLOFEN; BENZODIAZEPINE; BUSPIRONE; CANNABINOID 1 RECEPTOR ANTAGONIST; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CLOMETHIAZOLE; CLONIDINE; CLORAZEPATE; DIBENZEPIN; DISULFIRAM; GABAPENTIN; IMIPRAMINE; LORAZEPAM; MAPROTILINE; MEMANTINE; NALTREXONE; ONDANSETRON; PLACEBO; TEMAZEPAM; TETRABAMATE; THIORIDAZINE; TOPIRAMATE; TRIAZOLAM; VALPROIC ACID;

ABDOMINAL DISCOMFORT; ALCOHOL ABSTINENCE; ALCOHOL ABUSE; ALCOHOL INTOXICATION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTHRALGIA; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DECREASED APPETITE; DEPRESSION; DIARRHEA; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EPIGASTRIC DISCOMFORT; FATIGUE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEART INFARCTION; HUMAN; INCREASED APPETITE; LEG EDEMA; LIBIDO DISORDER; LOOSE FECES; LUNG DISEASE; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; MENTAL DISEASE; MORBIDITY; MORTALITY; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT COUNSELING; PEER GROUP; POLYURIA; PREVALENCE; PRURITUS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SHOULDER DISLOCATION; SIDE EFFECT; SKIN DISEASE; SLEEP DISORDER; SOMNOLENCE; STOMACH HEMORRHAGE; SUICIDE; TREATMENT DURATION; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE; VOMITING; WEIGHT GAIN;

ALCOHOL DETERRENTS; ALCOHOLISM; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAURINE;

ANIMALIA;

EID: 77249173934     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425251003641975     Document Type: Review

References (55)

1. World Health Organization. The World Health Report 2003. Geneva, Switzerland
2. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results for the Epidemiologic Catchment Area Study. JAMA 1990;264:2511-18
3. Substance Abuse and Mental Health Services Administration (SAMHSA). 2002 - 2004 National Survey on Drug Use and Health (NSDUH). Rockville, MD
4. Grant BF, Dawson DA. The 12-Month Prevalence and Trends in DSM-IV Alcohol Abuse and Dependence: United States, 1991 - 1992 and 2001 - 2002. Alcohol Res Health 2006;29:79-93
5. Harwood H. Updating estimates of the economic costs of alcohol abuse in the United States: estimates, update methods, and data. Report prepared by The Lewin Group for the National Institute on Alcohol Abuse and Alcoholism, 2000
6. Barnard EA, Skolnick P, et al. International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric-acid-a receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev 1998;50(2):291-313
7. Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci 2009;10(8):561-72
8. Doer PL, Kennedy WK, Boothby LA. Substance related disorders: alcohol, nicotine, and caffeine in pharmacotherapy (Chapter 69). In: DiPiro, Talbert, Yee, et al, editors, A pathophysiologic approach. 7th edition. ISBN: 9780071416139; McGraw Hill Medical Publishing; 2008
9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, version IV text revision. APA Press, 2000
10. Miller WR, Wilbourne PL, Hettema JE. What works? A summary of alcohol treatment outcome research. In: Hester RK, Miller WR, editors, Handbook of alcoholism treatment approaches: effective alternatives. 3rd edition. Pearson Education, Inc., Boston MA; 2003. p. 13-63
11. American Psychiatric Association. Practice guideline for the treatment of patients with substance use disorders, 2nd edition. In American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2006. Arlington, VA: American Psychiatric Association; 2006. p. 291-563). Available from: http://www.psych.org/psych-pract/ treatg/pg/SUD2ePG- 04-28-06.pdf
12. Campral [package insert]. Forest Pharmaceuticals, Inc. St Louis, Mo; 2005
13. Le Magnen J, Tran G, Durlach J, Martin C. Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by Ca-acetyl homotaurinate. Alcohol 1987;4:97-102
14. De Witte P, Littleton J, Parot P, Koob G. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs 2005;19:517-37
15. Spanagel R, Kiefer F. Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharmacol Sci 2008;29:109-15
16. Dahchour A, De Witte P, Bolo N, et al. Central effects of acamprosate: part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Res 1998;82:107-14
17. Littleton J. Acamprosate in alcohol dependence: implications of a unique mechanism of action. J Addict Med 2007;1:115-25
18. Chau P, Höifödt-Lidö H, Löf E, et al. Glycine receptors in the nucleus accumbens involved in the ethanol intake-reducing effect of acamprosate. Alcohol Clin Exp Res 2009 [Epub ahead of print]
19. Spanagel R, Zieglgansberger W. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci 1997;18:54-9
20. Johnson B, Ait-Daoud N. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology 2000;149:327-44
21. Johnson B. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 2008;75(1):34-56
22. Mann K, Kiefer F, Spanagel, Littleton J. Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 2008;32(7):1105-10
23. Brasser SM, McCaul ME, Houtsmuller EJ. Alcohol effects during acamprosate treatment: a dose-response study in humans. Alcohol Clin Exp Res 2004;28(7):1074-83
24. Johnson B, O'Malley S, Ciraulo D, et al. Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. J Clin Psychopharmacol 2003;23:281-93
25. Hammarberg A, Jayaram-Lindström N, Beck O, et al. The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. Psychopharmacology 2009;205:53-62
26. Mason B, Goodman A, Dixon R, et al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 2002;27:596-606
27. Mason BJ. Acamprosate in the treatment of alcohol dependence. Expert Opin Pharmacother 2005;6(12):2103-15
28. Saivin S, Hulot T, Chabac S, et al. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet 1998;35(5):331-45
29. Pelc I, Verbanck P, Le Bon O, et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry 1997;171:73-7
30. Sass H, Soyka M, Mann K, Zieglgänsberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996;53(8):673-80
31. Paille GM, Fuelfi JD, Perkins AC, et al. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 1995;30:239-47
32. Mann K, Lehert P, Morgan M. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004;28(1):51-63
33. Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res 2006;40(5):383-93
34. Kampman K, Pettinati H, Lynch K, et al. Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence. Addict Behav 2009;34:581-6
35. Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003;60(1):92-9
36. Anton RF, O'Malley SS, Ciraulo DA, et al. COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006;295(17):2003-17
37. Dranitsaris G, Selby P, Negrete J. Meta-analysis of placebo-controlled trials of acamprosate for the treatment of alcohol dependence. Impact of the combined pharmacotherapies and behavior interventions study. J Addict Med 2009;3(2):74-82
38. Kiefer F, Helwig H, Tarnaske T, et al. Pharmacological relapse prevention of alcoholism: clinical predictors of outcome. Eur Addict Res 2005;11:83-91
39. Lesch OM, Riegler A, Gutierrez K, et al. The European acamprosate trials: conclusions for research and therapy. J Biomed Sci 2001;8(1):89-95
40. Verheul R, Lehert P, Geerlings P, et al. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology 2005;178:167-73
41. Rosenthal RN, Gage A, Perhach JL, Goodman AM. Acamprosate: safety and tolerability in the treatment of alcohol dependence. J Addict Med 2008;2(1):40-50
42. Grant KA, Woolverton WL. Reinforcing and discriminative stimulus effects of Ca-acetyl homotaurine in animals. Pharmacol Biochem Behav 1989;32(3):607-11
43. Mason BJ. Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment. Eur Neuropsychopharmacol 2003;13(6):469-75
44. Morley KC, Teesson M, Reid SC, et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction. 2006;101(10):1451-62
45. Baltieri DA, De Andrade AG. Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting. J Stud Alcohol 2004;65(1):136-9
46. Namkoong K, Lee BO, Lee PG, et al. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol 2003;38(2):135-41
47. Gual A, Lehert P. Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol 2001;36(5):413-8
48. Tempesta E, Janiri L, Bignamini A, et al. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 2000;35(2):202-9
49. Chick J, Howlett H, Morgan MY, et al. United kingdom multicenter acamprosate study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 2000;35(2):176-87
50. Besson J, Aeby F, Kasas A, et al. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 1998;22(3):573-9
51. Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 1997;92(11):1537-46
52. Geerlings PJ, Ansoms C, Van den Brink W. Acamprosate and prevention of relapse inalcoholics.Resultsof a randomized, placebo-controlled double-blind study in out-patient alcoholics in the Netherlands, Belgium, and Luxembourg. Eur Addict Res 1997;3:129-37
53. Whitworth AB, Fischer F, Lesch OM, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996;347(9013):1438-42
54. Kiefer F, Andersohn F, Otte C, et al. Long-term effect of pharmacotherapy on relapse prevention in alcohol dependence. Acta Neuropsychiatr 2004;16:233-8
55. Niederhofer H, Staffen W. Acamprosate and its efficacy in treating alcohol dependent adolescents. Eur Child Adolesc Psychiatry 2003;12(3):144-8